Compare TPR & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPR | ZTS |
|---|---|---|
| Founded | 1941 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4B | 31.2B |
| IPO Year | 2000 | 2012 |
| Metric | TPR | ZTS |
|---|---|---|
| Price | $140.02 | $80.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 12 |
| Target Price | $145.44 | ★ $154.18 |
| AVG Volume (30 Days) | 2.4M | ★ 8.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | 1.13% | ★ 1.86% |
| EPS Growth | N/A | ★ 10.05 |
| EPS | ★ 5.58 | 1.42 |
| Revenue | $5,880,000,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | $12.39 | $5.63 |
| Revenue Next Year | $5.36 | $4.77 |
| P/E Ratio | ★ $25.19 | $56.82 |
| Revenue Growth | ★ 31.01 | 2.28 |
| 52 Week Low | $76.92 | $73.82 |
| 52 Week High | $161.97 | $172.23 |
| Indicator | TPR | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 28.35 |
| Support Level | $137.27 | $73.82 |
| Resistance Level | $151.11 | $129.32 |
| Average True Range (ATR) | 4.95 | 3.73 |
| MACD | 0.87 | 0.20 |
| Stochastic Oscillator | 54.94 | 16.63 |
Based in New York City, Tapestry is the parent company of accessories and fashion brand Coach, which accounted for 80% of its revenue and well over 90% of its operating profit in fiscal 2025. Handbags accounted for 58% of the brand's fiscal 2025 revenue. Coach products are sold through more than 900 company-owned stores, e-commerce, and third-party stores in North America, Asia, and Europe. Tapestry also owns Kate Spade (17% of fiscal 2025 revenue), which operates about 170 stores and generated 52% of its sales from handbags in fiscal 2025. Kate Spade is known for its colorful patterns and graphics. Tapestry sold its smallest brand, luxury footwear maker Stuart Weitzman, to Caleres in August 2025.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.